资本事件 | 格瑞农生物 【SynBioCon】 获 悉，近日， 武汉格瑞农生物科技有限公司 （以下简称：格瑞农生物）宣布完成 数千万元Pre-A+轮融资 。 本轮融资主要用于 深化噬菌体多应用场景技术布局，加速公司产品创新、 管线进展、证书申报、市场推广等工作 。 2024年12月，格瑞农生物宣布完成数千万元Pre-A轮融资。 2024年1月，格瑞农生物接连完成天使轮及天使+轮融资，累计募集资金近亿元。 格瑞农生物成立于2019年7月，是一家专注于噬菌体制剂研发与产业化的高新技术企业。 作为全球领先的噬菌体生物制造平台，通过"科研-生产-应用"全产业链布局， 深度赋能智慧养殖、生 态种植、绿色食品、生物医疗四大领域 ，现已成功构建了国际领先的噬菌体库及宿主菌库，为行业提 供了重要的科研支撑和资源平台。 格瑞农生物业务广泛覆盖动物保健（畜禽、水产）、植物保护、食品安全、消费医疗领域，已成功构建 起丰富的产品矩阵：动保领域开发了针对大肠杆菌、沙门氏菌、产气荚膜梭菌、鸭疫里氏杆菌、巴氏杆 菌、波氏杆菌及弧菌等多项噬菌体解决方案，显著降低畜禽细菌性疾病风险；植保领域则推出了推出青 枯病、溃疡病等作物重点病害的速效生 ...

Core Viewpoint - Evonik announced plans to optimize the global production layout of MetAMINO® (DL-methionine) in the third and fourth quarters of 2025, including temporary shutdowns of production facilities in Singapore and Antwerp to enhance energy efficiency and reduce CO2 emissions [1][4]. Group 1: Production Capacity and Market Dynamics - The global methionine production capacity is projected to reach 2.35 million tons per year by 2024, with Evonik, Adisseo, and Sinochem accounting for 71% of this capacity [4]. - China's methionine production capacity is expected to reach 840,000 tons per year by the end of 2024, representing 36% of the global total, with further expansion anticipated to exceed 1.2 million tons by 2029 [5][6]. - China has transitioned from a net importer to a net exporter of methionine, with a projected consumption of 430,000 tons in 2024, including 160,000 tons imported and 410,000 tons exported, resulting in a net export of 250,000 tons [6]. Group 2: Production Methods and Innovations - Biotechnological methods for producing methionine offer advantages over chemical methods, including higher efficiency and reduced safety risks associated with toxic substances [7]. - The industrialization of biological methionine production has been slow due to low yield during fermentation processes, with only one company, HJ, successfully achieving bulk production [9]. - In China, significant advancements in L-methionine biosynthesis have been made by academic teams, leading to the development of microbial cell factories for efficient precursor synthesis [11][12].

Core Viewpoint - The article discusses the development of an intelligent feedback control system for bioethanol fermentation, which integrates online Raman spectroscopy and deep learning to enhance the precision and real-time control of carbon source concentration during fermentation, addressing the limitations of traditional methods [1][7]. Group 1: System Innovation - The research team developed a spectral-time concatenation convolutional neural network (STC-CNN) model that utilizes non-destructive data streams from high-frequency online Raman spectroscopy to overcome issues such as prediction lag and lack of labeled data [3]. - Key innovations of the system include the introduction of a time series concatenation mechanism to capture dynamic changes in fermentation, a pseudo-label data augmentation strategy that expands the training sample size by 100 times, and the integration of a Kalman filter to enhance robustness under complex conditions [3][4]. Group 2: Performance Metrics - In practical applications, the system demonstrated significant advantages, achieving over 95% correlation between model predictions and offline HPLC measurements, with the maximum prediction deviation reduced from 8.3 g/L to 2.63 g/L [4]. - When controlling glucose concentration at 30 g/L, ethanol yield increased to 140.68 g/L, an 11.9% improvement over traditional batch fermentation, while glycerol concentration decreased to 6.72 g/L, resulting in a 64.6% increase in the ethanol/glycerol ratio [4][6]. Group 3: Broader Implications - The system not only addresses the precision control challenges in bioethanol production but also provides critical support for the intelligent transformation of the fermentation industry, reducing reliance on manual experience and enhancing process stability and production efficiency [7]. - The STC-CNN architecture and Raman feedback control system have been validated across various fermentation scenarios, indicating broad applicability in food, biopharmaceuticals, and green energy sectors [7].

Core Viewpoint - The company, Jupeng Bio, is the only global entity with an integrated technology chain for producing bioethanol and green methane from biomass gasification and gas fermentation, along with single-cell protein products [1][2]. Group 1: Technology Overview - Biomass Gasification: Converts carbon-containing biomass waste into synthesis gas, which can produce various green fuels and chemicals [3]. - Gas Fermentation: Includes CO/CO2 fermentation technologies for ethanol production and CO2 coupling green hydrogen fermentation for green methane, serving as effective pathways for CO2 direct reduction and efficient green hydrogen application [3]. - Single-Cell Protein: A high-nutrition and high-value biological product that can be used as aquaculture feed or developed into high-end downstream products such as peptides and culture media [4]. Group 2: Project Developments - In 2013, the first integrated demonstration plant for biomass gasification and gas fermentation to produce fuel ethanol was established in Florida, processing 250,000 tons of biomass annually and producing 24,000 tons of bioethanol, along with 6 MW of electricity [9]. - Jupeng Bio partnered with Shanxi Lu'an Chemical Group to construct an industrial waste gas fermentation plant in Changzhi, Shanxi, which began operations in October 2021 and has been validated for large-scale commercialization [9]. - A large-scale commercial facility with a capacity of 100,000 tons/year of ethanol and 20,000 tons/year of single-cell protein is set to begin construction in Ordos, Inner Mongolia, in November 2024 [9]. Group 3: Recognition and Certifications - In 2024, Jupeng Bio was recognized as a national high-tech enterprise and a "specialized, refined, and innovative" small and medium-sized enterprise in Beijing; the Shanxi plant was also recognized as one of the first high-tech enterprises in Shanxi Province [10].

Group 1: Core Insights - The article introduces the "Global Bio-based Industry Monthly Report," providing insights into the latest trends and opportunities in the bio-based sector [1][2][3] - The report is available for free to industry peers, highlighting the importance of collaboration and information sharing within the bio-based industry [1][3] Group 2: Policy Releases - Three domestic bio-based related policies were recorded in May 2025, focusing on carbon reduction projects, including biodegradable polyester rubber and sustainable aviation fuel [7][8] - Key projects include a 110,000-ton biodegradable polyester rubber demonstration project and a 1 million-ton sustainable aviation fuel project [8] Group 3: Industry Dynamics - The report includes updates on domestic bio-based chemical companies, such as the establishment of a lactate production line with an investment of 120 million yuan [9][10] - New companies in the bio-based sector are emerging, such as Yantai Wanhua Chemical, which has launched a new subsidiary focused on food additives [10] Group 4: Capital Events - Several financing events in the bio-based sector were reported, including a B round financing of several million yuan for Senqi New Materials and angel round financing for Zhongke Kexin [11][22] - Notable investments include over 100 million yuan for a recombinant collagen company and nearly 100 million yuan for a bioactive ingredient company [22] Group 5: Scientific Research Progress - Significant breakthroughs in bio-based materials research were highlighted, including the development of a new type of conductive "E-skin" for health sensing applications [12][23] - Research on bioremediation using engineered bacteria to address complex organic pollutants was also reported, showcasing advancements in environmental applications of synthetic biology [23] Group 6: Upcoming Events - The Fourth Synthetic Biology and Green Bio-manufacturing Conference is scheduled for August 20-22, 2025, in Jinan, Shandong, focusing on the future of bio-manufacturing and technology transfer [25][26]

Core Viewpoint - The integration of chemical and biological synthesis is essential for achieving efficient chemical bond activation, cleavage, and reorganization, emphasizing the collaborative potential of both methods [2][4]. Group 1: Chemical and Biological Synthesis - The core goal of chemical-biological synergy is to enhance efficiency and reduce costs by leveraging the strengths of both chemical and biological synthesis methods [2][4]. - Chemical synthesis will not be completely replaced by biological synthesis; instead, the focus is on how to complement each other to create lower-cost and higher-value pathways [4][5]. Group 2: Case Studies and Applications - Examples include the production of artemisinin, where biological synthesis converts sugars to artemisinic acid, while chemical methods enhance production efficiency through hydrogenation and oxidation [6]. - Collaborative efforts in various fields, such as polymer materials and drug development, have shown significant results, indicating a broad application prospect for chemical-biological synergy [6]. Group 3: Advances in Catalysis - Biomimetic catalysis is a key area where chemists learn from biologists, with future developments focusing on the diversity of catalytic systems and synergistic catalytic functions [7]. - Breakthroughs in artificial enzymes and non-natural reactions have been achieved by combining chemical catalysts with protein systems, providing new pathways for complex molecule synthesis [8]. Group 4: Innovations in Synthetic Biology - Combinatorial biosynthesis through genome recombination and editing generates non-natural products, with chemical methods playing a crucial role in precursor provision and subsequent modifications [9]. - The synthesis of nucleic acids, proteins, and carbohydrates faces challenges, but advancements are being made in functionalization and long DNA synthesis [11][12][13]. Group 5: Future Outlook and Technological Integration - AI and big data are poised to play significant roles in promoting the integration of chemical and biological synthesis, accelerating genome mining, molecular design, and synthesis pathway optimization [14]. - The deep-sea scientific program exemplifies the potential for protein and enzyme modification in extreme environments, showcasing innovative research directions [15]. Group 6: Policy and Support for Research - A call for national-level top-level design to promote interdisciplinary research in chemical-biological synergy, particularly supporting young researchers in fields like medicine, materials, energy, and carbon neutrality [16].

【SynBioCon】 获 悉， 6月12日， 苏州宜可生物科技有限公司 项目签约仪式在太湖新城隆重举行， 并于同日取得营业执照。吴中太湖新城党工委书记沈文群会见了公司创始人、澳大利亚莫道克大学兼任 副 教授Wilson Ling（林理坪）一行， 并共同见证签约。 #生物基产业进展 | 宜可生物 澳大利亚莫道克大学教授 Daniel Murphy（丹尼·墨菲），澳大利亚莫道克大学研究员Joseph Boctor （约瑟夫 · 波克特）特邀出席签 约仪式。 苏州宜可生物科技有限公司是 全球第一家拥有PCT专利生产PHA生物塑料树脂的企业 ，专注于可完 全降解的PHA生物塑料的研发与生产，致力于为 食品包装、医疗包装等领域提供高性能环保材料解决 方案 ，产品凭借其优异物性已成功应用于多个行业，并与多所大学开展产学研合作。 此次计划在太湖新城投资建设研发中心和生产基地，目标年产能 1万吨 ，分两期建设： 一期建设研发 中心和100吨中试产线；二期规划建设10000吨产线 。未来五年，公司将以技术创新为驱动，力争成为 生物塑料行业领军企业，实现全球化布局 。、 PHA材料正迎来快速增长的市场机遇 第四届合成生物与绿色 ...

Group 1: Policy Release - The report includes three domestic policies related to the bio-based industry released in May 2025, focusing on carbon reduction projects [7][18]. - Key projects include a 110,000-ton biodegradable polyester rubber demonstration project and a 1 million-ton waste oil processing sustainable aviation fuel project [8]. Group 2: Industry Dynamics - The report highlights two domestic bio-based chemical company updates, including a 120 million yuan investment in a lactic acid production demonstration line by Heilongjiang Guoke Bio-based New Materials [9]. - Wanhu Chemical has established a new company focusing on food additives, with a registered capital of 20 million yuan [10]. Group 3: Capital Events - Several financing events in the bio-based sector are reported, including a Series B round raising several million yuan for Senqi New Materials, focusing on bio-based high barrier film materials [11]. - Other notable investments include a multi-million yuan angel round for Zhongke Kexuan, specializing in fully natural degradable plastics [11]. Group 4: Scientific Research Progress - Significant breakthroughs in bio-based materials research are noted, including a study on lignin-derived carbon improving catalytic performance [12]. - Research on bio-inspired reconfigurable electronic skin has been developed, showcasing antibacterial properties for health sensing applications [12]. Group 5: Upcoming Events - The Fourth Synthetic Biology and Green Bio-manufacturing Conference will be held from August 20-22, 2025, in Jinan, Shandong, focusing on the development trends of the bio-manufacturing industry [25].

#全球政策进展 | 上海市 关于上海市2025年度关键技术研发计划"合成生物学"项目拟立项项目的公示 根据市科技计划项目管理办法有关规定，现将上海市2025年度关键技术研发计划"合成生物学"项目拟 立项项目予以公示。 | 图源：上海市科学技术委员会 | | --- | 公示链接：http://svc.stcsm.sh.gov.cn/public/guide 公示期：2025年6月12日至2025年6月18日 对公示内容持有异议的，请于公示期内以书面形式向我委反映。按照市科研失信行为调查处理办法有关 规定，个人提出异议的，请在异议材料上注明姓名和联系电话；单位提出异议的，请在异议材料上加盖 单位公章，并注明联系人和联系电话。我委对异议者的信息予以保密。为保证异议处理客观、公正、公 平，保护被公示者的合法权益，我委对匿名且无明确证据和可查线索的异议，不予受理。 材料寄送至：市科委科技人才处（上海市人民大道200号，邮编200003）。 投诉举报电话：60286858 业务咨询电话：8008205114（座机）、4008205114（手机） 上海市科学技术委员会 2025年6月12日 上海市2025年度关键技术研发 ...

Core Viewpoint - The company Xinghuo Technology plans to invest up to 3.3 billion RMB in a new amino acid production project in Daqing, Heilongjiang, with an expected annual revenue of approximately 3.9 billion RMB upon reaching full production capacity [1][10]. Project Information - Project Name: 450,000 tons amino acid and supporting engineering project [3] - Location: Daqing, Heilongjiang Province, covering approximately 483 acres [3] - Investment Entities: The project will be developed by the company's subsidiaries Heilongjiang Yipin Biotechnology and Heilongjiang Yipin Energy [3][4]. Project Construction Details - The project includes a new production line for 450,000 tons of amino acids, primarily producing 200,000 tons of feed-grade threonine and 250,000 tons of monosodium glutamate, along with related by-products [5]. - Supporting engineering will involve the construction of cogeneration and public service facilities to meet the project's heating and power needs [6]. Financial Overview - Total Investment: Up to 3.3 billion RMB, with approximately 2.95 billion RMB allocated for the amino acid production line and about 340 million RMB for supporting engineering [7]. - Funding Sources: The investment will be financed through a combination of the company's own funds and bank loans, each accounting for approximately 50% [8]. - Construction Timeline: The project is expected to take 22 months to complete [9]. Economic Benefits - Estimated Annual Revenue: Upon reaching full production and sales, the project is expected to generate around 3.9 billion RMB in annual sales, with a gross margin of approximately 10% [10]. - Investment Recovery: The estimated payback period for the investment is about 8.5 years, excluding the construction period [10]. Market Analysis - The demand for feed amino acids is increasing due to national policies promoting reduced soybean meal usage, alongside rising consumer demand for animal products [11]. - Monosodium glutamate, as a fundamental seasoning in the food industry, continues to see stable growth in production and consumption, particularly driven by the expanding ready-to-eat meal market [11]. 2024 Business Outlook - Projected Revenue: In 2024, the company anticipates revenues of 4.248 billion RMB from food additives, 11.734 billion RMB from feed additives, and other segments contributing smaller amounts [12]. - Profitability: Despite a slight decline in overall revenue due to falling market prices, increased sales volume is expected to mitigate some of the revenue loss, with gross and net profit margins improving [12].